Baecklund Eva, Backlin Carin, Iliadou Anastasia, Granath Fredrik, Ekbom Anders, Amini Rose-Marie, Feltelius Nils, Enblad Gunilla, Sundström Christer, Klareskog Lars, Askling Johan, Rosenquist Richard
Department of Rheumatology, Akademiska Hospital, Uppsala, Sweden.
Arthritis Rheum. 2006 Dec;54(12):3774-81. doi: 10.1002/art.22277.
Patients with rheumatoid arthritis (RA) are at increased risk of malignant lymphomas, with a correlation between RA disease severity and lymphoma risk, most pronounced for diffuse large B cell lymphomas (DLBCLs), which also constitute the majority of RA-associated lymphomas. DLBCLs can be further subdivided into germinal center (GC)-like and non-GC-like subtypes, with different cellular origins and prognoses. This study was undertaken to investigate whether RA displays a specific association with any of the DLBCL subtypes.
We identified 139 patients with DLBCLs within a population-based case-control study of 378 RA patients with lymphoma. The DLBCLs were examined for CD10, Bcl-6, and interferon regulatory factor 4 expression patterns, subclassified into GC and non-GC subtypes, and then correlated with clinical parameters.
We found a statistically significant predominance of the non-GC subtype (97 patients; 70% of all DLBCLs). These patients more often had an advanced stage of lymphoma at diagnosis and had a worse 5-year overall survival rate (16% versus 33%) compared with patients with the GC subtype. There was a strong association with RA disease activity in both subtypes, with >70% of the GC and non-GC cases occurring in RA patients with the highest overall disease activity scores.
These findings suggest that severe RA is particularly associated with the non-GC subtype of DLBCL, and indicate a critical role of activated peripheral B cells as the cells of origin in these lymphomas.
类风湿关节炎(RA)患者发生恶性淋巴瘤的风险增加,RA疾病严重程度与淋巴瘤风险之间存在相关性,这在弥漫性大B细胞淋巴瘤(DLBCL)中最为明显,DLBCL也是RA相关淋巴瘤的主要类型。DLBCL可进一步细分为生发中心(GC)样和非GC样亚型,具有不同的细胞起源和预后。本研究旨在调查RA是否与任何DLBCL亚型存在特定关联。
在一项对378例患有淋巴瘤的RA患者进行的基于人群的病例对照研究中,我们确定了139例DLBCL患者。对DLBCL进行CD10、Bcl-6和干扰素调节因子4表达模式检测,分为GC和非GC亚型,然后与临床参数进行关联分析。
我们发现非GC亚型在统计学上占显著优势(97例患者;占所有DLBCL的70%)。与GC亚型患者相比,这些患者在诊断时淋巴瘤分期更晚,5年总生存率更差(分别为16%和33%)。两种亚型均与RA疾病活动密切相关,超过70%的GC和非GC病例发生在总体疾病活动评分最高的RA患者中。
这些发现表明,严重RA与DLBCL的非GC亚型特别相关,并表明活化的外周B细胞作为这些淋巴瘤的起源细胞起着关键作用。